【摘要】 目的观察非甾体消炎药在动物体内抑制胃癌NF-κB激活的效应,探讨其抗癌机制。方法建立人胃癌细胞SGC7901裸鼠种植瘤模型,随机分为3组:舒林酸组(8 mg)、塞来昔布组(10 mg)和对照组(阿拉伯树胶50mg);采用ELISA法检测活性NFκ-B水平。结果舒林酸组(0.46±0.31)和塞来昔布组(0.23±0.08)活性NF-κB水平较对照组(0.84±0.58)明显下降(F分别为3.98、3.65,P均<0.05),舒林酸组与塞来昔布组之间差异无显著性(P>0.05)。结论非甾体消炎药在体内具有显著抗胃癌效应,抑制NFκ-B激活可能是其发挥抗癌的机制之一。更多还原

【Abstract】 Objective To observe the inhibitory effects in vivo of nonsteroidal antiinflammatory drugs(NSAIDs) on activation of NF-κB in gastric cancer of animal model,further to investigate their anti-cancer mechanisms.Methods Thirty athymic mice’s xenograft models with human gastric cancer cell SGC7901 were established and divided randomly into three groups: sulindac group(8 mg),celecoxib group(10 mg),and control group(Arabic gel 50 mg).TransAM NFκB p50 Transcription Factor Assay Kit was applied to detect the level of activating NF-κB.Results Sulindac and celecoxib both markedly depressed the activation of NF-κB.The ANOVA analysis showed the activating NF-κB levels of both sulindac and celecoxib groups(0.46 ± 0.31,0.23 ± 0.08,respectively) were significantly lower than that of control group(0.84 ± 0.58,F = 3.98 and F = 3.65,P<0.05 in both),but no differences of activating NF-κB level showed between two drug groups.Conclusion The NSAIDs had obvious anti-cancer effects in vivo against gastric cancer,and inhibiting the activation of NF-κB might be one of their anti-cancer mechanisms.更多还原